Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

瑞博西尼(Ribociclib) 凯丽隆

Ribociclib (English: Ribociclib), brand name KISQALI, is a CDK4/6 inhibitor type breast cancer drug [1][2], developed by Astex and Novartis Pharmaceuticals [3]. Applicable subjects are: hormone receptor-positive, HER2-negative patients, and postmenopausal patients with advanced breast cancer.


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.